Aldose reductase inhibition by .gamma.-oxo-8-fluoranthenebutanoic acid
AssigneeAyerst McKenna and Harrison Ltd.
InventorsDushan M. Dvornik, Nicole Simard-Duquesne
Life of this patent
Estimating the term…
Abstract
Disclosed are new methods of using .gamma.-oxo-8-fluoranthenebutanoic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes mellitus. The compound inhibits lens aldose reductase in a diabetic mammal.
Claims4
A method of preventing or relieving a diabetic complication in a diabetic mammal which comprises administering to said mammal an effective alleviating or prophylactic amount of .gamma.-oxo-8-fluoranthenebutanoic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base.
A method of preventing or relieving diabetes mellitus associated complications consisting of cataracts and retinopathy in a diabetic mammal which comprises topically administering to said mammal an effective alleviating or prophylactic amount of a sterile aqueous solution of .gamma.-oxo-8-fluoranthenebutanoic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base.
A method of preventing or relieving diabetes mellitus associated complications consisting of neuropathy and nephropathy in a diabetic mammal which comprises orally or parenterally administering to said mammal an effective alleviating or prophylactic amount of .gamma.-oxo-8-fluoranthenebutanoic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base.
Dependencies are inferred from the claim text.